- Conditions
- Hepatitis C
- Interventions
- Telaprevir, Peginterferon alfa-2a, Ribavirin, Vitamin D
- Drug · Dietary Supplement
- Lead sponsor
- Timothy Morgan, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 4
- States / cities
- Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 150
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hepatitis C Infection, HIV Infection
- Interventions
- Nitazoxanide With Pegylated Interferon And Ribavirin
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Hepatitis C
- Interventions
- Pegylated Interferon Lambda (pegIFNλ), BMS-790052 (NS5A Inhibitor), Ribavirin (RBV), BMS-650032 (NS3 Protease Inhibitor), Pegylated Interferon Alfa-2a (pegIFNα-2a), Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor), Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor), Placebo for Ribavirin (RBV)
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Palm Springs, California • Aurora, Colorado + 10 more
- Conditions
- Hepatitis C Infection, Thrombocytopenia
- Interventions
- romiplostim, ribavirin, placebo, PEG-interferon alfa-2a, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hepatitis C Virus
- Interventions
- BMS-791325, Placebo, Peg-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 10
- States / cities
- Anaheim, California • Maywood, Illinois • Baltimore, Maryland + 6 more
- Conditions
- Hepatitis C
- Interventions
- TMC435, Ribavirin (R), PegIFNα-2a (P), Placebo
- Drug
- Lead sponsor
- Tibotec Pharmaceuticals, Ireland
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 386 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Jacksonville, Florida • Orlando, Florida + 9 more
- Conditions
- Hepatitis C, Human Immunodeficiency Virus, HIV Infections
- Interventions
- Pegylated interferon alfa-2a + Ribavirin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Hepatitis C
- Interventions
- CTS-1027, Pegylated interferon, Ribavirin
- Drug
- Lead sponsor
- Conatus Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 14
- States / cities
- La Jolla, California • San Diego, California • Denver, Colorado + 10 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GSK2336805 40 mg, GSK2336805 60 mg, Pegylated interferon alpha-2a, Ribavirin, Telaprevir
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 18
- States / cities
- Dothan, Alabama • Anaheim, California • Los Angeles, California + 15 more
- Conditions
- Genotype 1 Chronic Hepatitis C, Treatment Naive
- Interventions
- Ribavirin, Telaprevir, Pegylated interferon alfa-2a
- Drug
- Lead sponsor
- Janssen Infectious Diseases BVBA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 744 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 37
- States / cities
- La Jolla, California • Los Angeles, California • San Diego, California + 34 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Sofosbuvir, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 332 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 44
- States / cities
- Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Pegylated-interferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Sacramento, California • San Francisco, California • Lutherville, Maryland + 8 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin, ritonavir
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Anaheim, California • Coronado, California + 11 more
- Conditions
- Chronic Hepatitis C Virus Genotype 1
- Interventions
- BMS-824393, Placebo, Peginterferon Alpha-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 11
- States / cities
- Coronado, California • San Diego, California • Washington D.C., District of Columbia + 8 more
- Conditions
- Hepatitis C
- Interventions
- Alisporivir, Peginterferon alfa-2a, Ribavirin, ALV Placebo
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1,081 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Beverly Hills, California • Oakland, California • San Diego, California + 23 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Copegus, Pegasys, RO5024048
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 413 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2012
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more
- Conditions
- Hepatitis C
- Interventions
- Daclatasvir, Peg-Interferon Alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 448 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 35
- States / cities
- Montgomery, Alabama • Long Beach, California • Los Angeles, California + 24 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- peginterferon alfa-2a, Ribavirin
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 74 more
- Conditions
- Hepatitis C Infection
- Interventions
- Daclatasvir, Placebo, Peginterferon alpha-2a, ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 74 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 11
- States / cities
- Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more
- Conditions
- Chronic Hepatitis C
- Interventions
- Pegylated Interferon/ribavirin
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 5 Years to 18 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Washington D.C., District of Columbia + 8 more
- Conditions
- Chronic Hepatitis C
- Interventions
- NM283 plus Peg-IFNα-2a
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 114 participants
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia • Fairfax, Virginia
- Conditions
- Hepatitis C, Hepatitis
- Interventions
- Merimepodib, PEG-Interferon-alpha 2a (Pegasys®), Ribavirin (Copegus®)
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 67
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 55 more
- Conditions
- Hepatitis C Virus
- Interventions
- Pegylated-Interferon-lambda, Ribavirin, Daclatasvir
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 4
- States / cities
- Palo Alto, California • Chicago, Illinois • Philadelphia, Pennsylvania + 1 more
- Conditions
- Hepatitis C
- Interventions
- BMS-790052 (NS5A Replication Complex Inhibitor), Placebo matching BMS-790052, Pegylated-interferon alfa 2a, Ribavirin
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 4
- States / cities
- San Clemente, California • Worcester, Massachusetts • Providence, Rhode Island + 1 more